BioLineRx (BLRX) Gross Margin (2024 - 2026)
BioLineRx (BLRX) posted quarterly Gross Margin of 79.38% for Q4 2025, up 3121.0% year-over-year from 2.46% in Q4 2024, and down 1.18% quarter-over-quarter from 80.33% in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Gross Margin (2024 - 2026) Analysis & Trends
BioLineRx's Gross Margin history runs 2 years deep, the most recent figure standing at 79.38% for Q4 2025.
- In Q4 2025, Gross Margin rose 3121.0% year-over-year to 79.38%; the TTM figure through Dec 2025 stood at 80.51% (up 1252.0% YoY), while the FY2025 annual figure was 80.51%, up 1252.0% from the prior year.
- Gross Margin for Q4 2025 stood at 79.38%, down from 80.33% in the prior quarter.
- The five-year high for Gross Margin was 86.67% in Q1 2025, with the low at 48.17% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 10 | BioLineRx | 6.53 Bn | 6.53 Bn | 235,000.00 | 79.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79.93% |
| Mar 31, 2026 | 80.08% |
| Dec 31, 2025 | 79.38% |
| Sep 30, 2025 | 80.33% |
| Jun 30, 2025 | 76.32% |
| Mar 31, 2025 | 86.67% |
| Dec 31, 2024 | 48.17% |
| Sep 30, 2024 | 83.37% |
| Jun 30, 2024 | 83.37% |
| Mar 31, 2024 | 78.77% |